Oppenheimer raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $58 from $51 and keeps an Outperform rating on the shares. The firm notes that on Tuesday, Corbus announced Q4 and full year results, highlighting pipeline advances in both oncology and obesity. While Corbus’ CB1R targeting obesity program has long flown under the radar, following Novo Nordisk’s (NVO) recent update on the target, Oppenheimer thinks it is time to pay attention.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRBP:
- Corbus Pharmaceuticals Shares Informal Financial Snapshot
- Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- One new option listing on March 6th
- Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
- Corbus Pharmaceuticals upgraded to Buy from Hold at Jefferies
